Transdermal Dextroamphetamine (Xelstrym) for ADHD

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2023 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2023

Data sources: Europe PubMed Central

Transdermal Dextroamphetamine (Xelstrym) for ADHD

descriptionPublicationkeyboard_double_arrow_right Article 06 Feb 2023Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 65, pages 22-24 (eissn: 1523-2859,

Copyright policy )

doi: 10.58347/tml.2023.1669d

pmid: 36757350

Transdermal Dextroamphetamine (Xelstrym) for ADHD

- Summary
- Subjects
- Metrics

Abstract

The FDA has approved a dextroamphetamine transdermal patch (Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first transdermal amphetamine product to be approved in the US. A methylphenidate transdermal patch (Daytrana, and generics) has been available for years for treatment of ADHD.

Keywords

Dextroamphetamine, Attention Deficit Disorder with Hyperactivity, Methylphenidate, Humans, Central Nervous System Stimulants, Administration, Cutaneous

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average